Effects of magnesium citrate, magnesium oxide and magnesium sulfate on arterial stiffness 143 6 Supplemental Table 1. Adherence to the treatments groups, reasons for discontinuation and GI adverse events over 24-wk follow-up. Magnesium citrate Magnesium oxide Magnesium sulfate Placebo Adherence Compliance*, % 96 ± 5 93 ± 8 94 ± 7 90 ± 15 Reasons for discontinuation GI symptoms, n (%) 2 (4.3) 0 (0) 2 (4.3) 2 (7.7) Other symptoms, n (%) 0 (0) 1 (2.2) 0 (0) 0 (0) GI adverse events † Flatulence, n (%) 4 (8.7) 2 (4.3) 2 (4.3) 2 (7.7) Stomach pain, n (%) 1 (2.2) 5 (10.9) 4 (8.7) 3 (11.5) Mild diarrhea, n (%) 5 (10.9) 1 (2.2) 5 (10.9) 2 (7.7) Nausea, n (%) 3 (6.5) 2 (4.3) 2 (4.3) 1 (3.8) Bloating, n (%) 1 (2.2) 1 (2.2) 2 (4.3) 1 (3.8) Constipation, n (%) 2 (4.3) 0 (0) 0 (0) 0 (0) *Mean compliance (± SD) was calculated as the percentage of the total capsule intake (based on the returned capsules). †Derived from subjects’ study diaries. GI; gastro-intestinal. Supplemental Table 2. Effects of magnesium citrate, magnesium oxide and magnesium sulfate (vs placebo) on plasma minerals. Magnesium citrate (n=46) Magnesium oxide (n=46) Magnesium sulfate (n=46) Placebo (n=26) Plasma calcium 2-wk Mean, mmol/L 2.25 ± 0.08 2.26 ± 0.08 2.27 ± 0.07 2.25 ± 0.12 Difference vs placebo -0.02 (-0.01; 0.05) 0.03 (-0.00; 0.06) 0.02 (-0.01; 0.05) .. 12-wk Mean, mmol/L 2.25 ± 0.07 2.26 ± 0.09 2.28 ± 0.07 2.26 ± 0.07 Difference vs placebo -0.01 (-0.03; 0.04) 0.01 (-0.02; 0.04) 0.01 (-0.02; 0.04) .. 24-wk Mean, m/s 2.27 ± 0.06 2.28 ± 0.09 2.28 ± 0.07 2.29 ± 0.08 Difference vs placebo -0.00 (-0.03; 0.03) -0.01 (-0.04; 0.03) -0.02 (-0.05; 0.01) .. Plasma potassium 2-wk Mean, mmol/L 4.2 ± 0.4 4.2 ± 0.3 4.2 ± 0.3 4.1 ± 0.2 Difference vs placebo 0.1 (-0.1; 0.2) 0.1 (-0.1; 0.2) 0.0 (-0.1; 0.2) .. 12-wk Mean, mmol/L 4.1 ± 0.3 4.2 ± 0.4 4.2 ± 0.3 4.1 ± 0.3 Difference vs placebo 0.0 (-0.2; 0.2) 0.1 (-0.1; 0.2) 0.0 (-0.1; 0.2) ..
RkJQdWJsaXNoZXIy MTk4NDMw